However, the agency noted officials cannot rule out that 'a small risk may exist,' and it will continue to investigate
No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications
FDA is investigating reports of hair loss, aspiration, and suicidal thoughts among people taking the medications
Three case reports from Iceland spurred the review; two of the cases involved Ozempic
Evidence lacking that MI makes meaningful difference to weight loss, well-being when added to behavioral weight management program
<p>Findings seen regardless of whether a person has normal, overweight, or obese BMI at baseline</p>